The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel--a drug used to treat rheumatoid arthritis and other inflammatory conditions--allowing Amgen to extend its monopoly over the biologic drug.
View Press Release: https://www.ftc.gov/news-events/news/press-releases/2026/08/ftc-files-amicus-brief-protect-competition-biologic-drug-markets
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.